DR. TALIA ZAHRA M.D.
Prescription History 1902165129
Internal Medicine - Hematology & Oncology in Miami, FL


Quality Rating: 64.79 out of 100 score

NPI Status: Active since May 08, 2012

Contact Information

8900 N. KENDALL DR
MIAMI CANCER INSTITUTE
MIAMI, FL
ZIP 33176
Phone: (786) 596-2000
Fax: (305) 279-7778

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. TALIA ZAHRA M.D., an active Hematology & Oncology specialist practicing in Miami, FL. Our medical registry currently tracks 11 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 259 documented patient claims. Among these therapy options, the most frequently utilized medication is Acyclovir, which accounts for 66 claims alone.


Acyclovir

Generic Formulation: AcyclovirSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 66
30-Day Fills 108.0
Days Supply 3,220
FL State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills38.1
Peer Average Days Supply1,001
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 187.0% higher than the standard regional baseline profile for FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,455.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.05

State Avg Cost Per Claim

$30.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Therapeutic Applications

Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections.

Atovaquone

Generic Formulation: AtovaquoneSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 31
30-Day Fills 31.0
Days Supply 857
FL State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills25.0
Peer Average Days Supply698
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 34.8% more claims than the standard regional baseline profile for FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $24,187.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$780.24

State Avg Cost Per Claim

$1,029.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.

Therapeutic Applications

Atovaquone is used to prevent or treat a serious lung infection called Pneumocystis pneumonia (PCP). This medication helps to stop infection symptoms such as fever, cough, tiredness, and shortness of breath.

Eliquis

Generic Formulation: ApixabanSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 23
30-Day Fills 33.0
Days Supply 961
FL State Average Benchmarks
Peer Average Claims79.0
Peer Average 30-Day Fills130.4
Peer Average Days Supply3,717
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.9% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $19,282.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$838.39

State Avg Cost Per Claim

$852.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Iclusig

Generic Formulation: Ponatinib HclSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
FL State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills13.5
Peer Average Days Supply402
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $225,149.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$20,468.14

State Avg Cost Per Claim

$20,281.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Ponatinib is used to treat certain types of blood cancer (chronic myelogenous leukemia-CML, acute lymphoblastic leukemia-ALL). It works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Levofloxacin

Generic Formulation: LevofloxacinSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 250
FL State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.6
Peer Average Days Supply220
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.8% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $107.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.96

State Avg Cost Per Claim

$8.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The L-isomer of Ofloxacin.

Therapeutic Applications

This medication is used to treat a variety of bacterial infections. Levofloxacin belongs to a class of drugs known as quinolone antibiotics. It works by stopping the growth of bacteria. Levofloxacin injection is used if you cannot take the medication by mouth. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 440
FL State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.7
Peer Average Days Supply418
Conservative Utilization

This provider writes prescriptions for this formulation 35.7% less frequently than the standard regional baseline metric for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $215.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.99

State Avg Cost Per Claim

$7.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Sprycel

Generic Formulation: DasatinibSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 630
FL State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.4
Peer Average Days Supply536
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $205,018.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,762.76

State Avg Cost Per Claim

$12,136.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.

Therapeutic Applications

This medication is used to treat certain types of cancer (chronic myeloid leukemia-CML, acute lymphoblastic leukemia-ALL). It works by slowing or stopping the growth of cancer cells.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.6
Days Supply 505
FL State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills31.0
Peer Average Days Supply374
Conservative Utilization

This provider writes prescriptions for this formulation 39.3% less frequently than the standard regional baseline metric for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $116.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.84

State Avg Cost Per Claim

$5.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Ursodiol

Generic Formulation: UrsodiolSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 600
FL State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills41.1
Peer Average Days Supply1,218
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,986.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$99.33

State Avg Cost Per Claim

$265.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.

Therapeutic Applications

Ursodiol is used to dissolve certain types of gallstones, to prevent gallstones from forming in obese patients who are losing weight rapidly, and to treat a certain type of liver disease (primary biliary cholangitis). Ursodiol is a bile acid.

Venclexta

Generic Formulation: VenetoclaxSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 24
30-Day Fills 24.0
Days Supply 636
FL State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.2
Peer Average Days Supply670
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $178,453.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$7,435.54

State Avg Cost Per Claim

$8,886.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (chronic lymphocytic leukemia-CLL, small lymphocytic lymphoma-SLL, acute myeloid leukemia-AML). Venetoclax is a drug that works by helping to slow or stop the growth of cancer cells.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 16
30-Day Fills 18.0
Days Supply 540
FL State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills82.4
Peer Average Days Supply2,380
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.2% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,220.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$576.26

State Avg Cost Per Claim

$917.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. TALIA ZAHRA M.D. provides transparency into local medical care patterns within Miami, FL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.